Findings have implications for reducing venous thromboembolisms
Biologics’ use poses nominal postoperative infection risk
Results of largest medical records-based analysis to date
Infliximab-abda offers similar benefits at lower costs
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A cost-effective alternative to enoxaparin?
Results of the largest population-based study to date
What to look for and when to use immunosuppressive medications
Rate is lower with tunneled intravenous catheters
Risk reduction guidelines
Too few patients assessed before undergoing biologic dose changes